Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation
about
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and managementVenous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.Postpartal recurrent non-ST elevation myocardial infarction in essential thrombocythaemia: case report and review of the literature.Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.Chronic myeloproliferative neoplasms: a collaborative approach.How I treat essential thrombocythemia.A Successful Mother and Neonate Outcome for a Woman with Essential Thrombocytosis and FV Leiden Heterozygosity.Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Treatment options for essential thrombocythemia and polycythemia vera.Special issues in myeloproliferative neoplasms.A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.How we diagnose and treat essential thrombocythaemia.Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.Thrombotic risk correlates with mutational status in true essential thrombocythemia.Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study.Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series.Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia.Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.Pregnancy and myeloproliferative neoplasms : A retrospective monocentric cohort.A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective.Pregnancy complications predict thrombotic events in young women with essential thrombocythemia.Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review.Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.Impact of common thrombophilias and JAK2 V617F on pregnancy outcomes in unselected Italian women.How to manage polycythemia vera.
P2860
Q26851894-CBF06DE9-2762-4638-AEA7-CFD98CC6D83CQ33398180-24B67F49-BF4A-4928-9087-029BCC8869E5Q33434734-22A61708-671D-403A-8C94-5E4474204CF1Q34016598-87F50182-E7C2-4699-B02F-85585A20B9E6Q34166859-F335A691-8E38-4B49-A49A-9330AC24166AQ34451630-4ABF5305-F725-4874-B87D-6225CA5C1E3FQ34549335-7CED59E1-C410-4612-AA86-A0F3F926BC1CQ35132271-EAC4A1FC-61F3-458C-8CCF-2BA104C25208Q36795522-9F98665B-9C47-4B1F-9C35-40CBB5D863BCQ37163590-8DA16962-1F6B-41EA-BA9B-D929D762CE30Q37810107-5E5F3FB4-BD88-47E3-99CE-7EA91DE85DBFQ37823434-1F1FFF91-0BFE-43D1-9C1D-2B37DC27CDBFQ37955231-475BD3FA-624B-45D5-AB05-6BB2343360BCQ37983791-9C323E6C-03DE-4A6C-8286-88AB6BDADB7AQ38606595-97EF147A-2B5D-4EC7-B782-B750D965EB57Q39306368-CFB23A75-4ECF-46FB-B838-4530FD53C2FCQ39704198-0B09DA50-677C-4938-8197-933D3D5A92F3Q40587986-81D675B5-61C8-46B2-B1F0-E01BD6826E3AQ42399873-4CD84EC2-83AE-489D-BDE9-4F05613D200AQ42758710-A873AFEF-D40F-439C-8EBE-708A6BE0ABE7Q46636672-501D7A2B-A4A2-434A-A3B1-C6E79021DFE3Q47334212-2BE89549-88C3-4451-9EF6-00F7E0F87E2EQ47813570-77C6A4BF-2062-4A6D-8FBA-809BB69124F7Q47824825-12038365-12EB-4C81-946B-18C3396511A5Q48327487-307B0889-531F-4D84-9B00-40B0C920AF58Q50576885-1185766B-BFDF-44BA-9493-F484AEB96036Q54392855-6D3FDB59-34F6-4048-B85F-DB9D6571E17EQ54544165-C600FBA6-D284-420C-AB32-7A1BF0E5B173
P2860
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Increased risk of pregnancy co ...... ing the JAK2 (617V>F) mutation
@ast
Increased risk of pregnancy co ...... ing the JAK2 (617V>F) mutation
@en
Increased risk of pregnancy co ...... ing the JAK2 (617V>F) mutation
@nl
type
label
Increased risk of pregnancy co ...... ing the JAK2 (617V>F) mutation
@ast
Increased risk of pregnancy co ...... ing the JAK2 (617V>F) mutation
@en
Increased risk of pregnancy co ...... ing the JAK2 (617V>F) mutation
@nl
prefLabel
Increased risk of pregnancy co ...... ing the JAK2 (617V>F) mutation
@ast
Increased risk of pregnancy co ...... ing the JAK2 (617V>F) mutation
@en
Increased risk of pregnancy co ...... ing the JAK2 (617V>F) mutation
@nl
P2093
P50
P3181
P1433
P1476
Increased risk of pregnancy co ...... ing the JAK2 (617V>F) mutation
@en
P2093
Chiara Elena
Cristiana Pascutto
Elisa Rumi
Enrica Morra
Ester Pungolino
Fabiana Tezza
Fabrizio Fabris
Margherita Scapin
Maria Luigia Randi
Mario Cazzola
P304
P3181
P356
10.1182/BLOOD-2007-01-071068
P407
P577
2007-04-10T00:00:00Z